A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma Cell Disorders Including Multiple Myeloma
MD Anderson Study Status
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Multiple Myeloma, Plasma Cell Disorder
For general questions about clinical trials: